Thailand Pharmaceuticals and Healthcare Report

Overprescribing and overuse of medicines likely to be tackled in coming years. Free pricing policy in non-institutional sectors, which has been blamed for profiteering, likely to come under scrutiny. ...Government sector reforms capping patient payments for a wide range of treatments potentially leading to a deceleration in market development. Government reliance on copy drugs manufactured exclusively by state-owned producers to discourage multinational expansion within the HIV/AIDS therapeutic market in particular. Use of health economics requirements to threaten values of patented drugs. ...Use of health economics requirements to threaten values of patented drugs. Political conflicts between the National Health Security Office and the Ministry of Public Health can affect provision of medical services.

...BMI View: Reforms to Thailand s healthcare system will influence the commercial opportunities for multinational drugmakers. While a merger of all three schemes remains difficult, incremental reforms in that direction will be forthcoming and necessary for Thailand to address inequalities in healthcare outcomes. ...BMI View: Reforms to Thailand s healthcare system will influence the commercial opportunities for multinational drugmakers. While a merger of all three schemes remains difficult, incremental reforms in that direction will be forthcoming and necessary for Thailand to address inequalities in healthcare outcomes. Pressures to ensure the sustainability of the country s healthcare programmes have also not abated. ...Pressures to ensure the sustainability of the country s healthcare programmes have also not abated. This accentuates the threat of cost containment for drugmakers, which will be heightened should Thailand pursue the target - set by the Committee on Resource Mobilisation for Sustainable Universal Health Coverage - of keeping total health spending less than - of GDP by ----.

...Domestic patent law notably below international standards. High levels of counterfeit and parallel imported medicines in the country. ...